BioRestorative Therapies to Report Second Quarter 2024 Financial Results and Host Conference Call on August 13, 2024
06 août 2024 16h05 HE
|
BioRestorative Therapies, Inc
MELVILLE, N.Y., Aug. 06, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based...
BioRestorative Therapies Announces Notice of Allowance for Patent Covering Fundamental Aspect of ThermoStem® Metabolic Disease Program
27 juin 2024 07h40 HE
|
BioRestorative Therapies, Inc
– Adds to comprehensive patent portfolio underlying novel ThermoStem® technology platform – – Expanding intellectual property estate expected to help drive ThermoStem® licensing opportunities – –...
BioRestorative Therapies Regains Compliance with Nasdaq Listing Rule 5250(c)(1); Reports First Quarter 2024 Financial Results
17 juin 2024 07h05 HE
|
BioRestorative Therapies, Inc
- Significant YoY improvement in operating performance - - Ends Q1-2024 with $16.4 million cash, cash equivalents, and marketable securities - MELVILLE, N.Y., June 17, 2024 (GLOBE NEWSWIRE) --...
BioRestorative Therapies Provides First Quarter 2024 Business Update
14 mai 2024 16h10 HE
|
BioRestorative Therapies, Inc
MELVILLE, N.Y., May 14, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based...
BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment
16 avr. 2024 07h45 HE
|
BioRestorative Therapies, Inc
— Amendment replaces saline injections with sham injections in the control group — MELVILLE, N.Y., April 16, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or...
BioRestorative Therapies Announces Filing of Form S-1 Registration Statement to Register for Resale Common Stock Underlying Previously Issued Warrants
03 avr. 2024 16h38 HE
|
BioRestorative Therapies, Inc
- Company is not offering shares pursuant to the registration statement - MELVILLE, N.Y., April 03, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the...
BioRestorative Therapies Announces Filing of 2023 Annual Report on Form 10-K
01 avr. 2024 07h45 HE
|
BioRestorative Therapies, Inc
MELVILLE, N.Y., April 01, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based...
BioRestorative Therapies to Participate in the 36th Annual ROTH Conference
11 mars 2024 16h15 HE
|
BioRestorative Therapies, Inc
MELVILLE, N.Y., March 11, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies,...
BioRestorative Therapies Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $8.1 Million Gross Proceeds Priced At-the-Market
06 févr. 2024 08h05 HE
|
BioRestorative Therapies, Inc
MELVILEE, N.Y., Feb. 06, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative" or the “Company”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies,...
BioRestorative Therapies Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease
05 févr. 2024 07h30 HE
|
BioRestorative Therapies, Inc
— Preliminary data includes 26 and 52-week follow-up end points as part of ongoing Phase 2 trial — — Company to host webcasted conference call today at 8:30am EST — MELVILLE, N.Y., Feb. 05,...